Apogee Therapeutics, Inc. Common Stock

APGENASDAQUSD
134.00 USD
0.08 (0.06%)AT CLOSE (11:59 AM EDT)
133.78
0.22 (0.17%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
133.78
0.22 (0.17%)
🔴Market: CLOSED

Shares of Apogee Therapeutics, Inc. Common Stock (APGE) are trading at $134.00. Our models show a "Buy" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, APGE is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Jul 17, 2026.

Open?$134.01
High?$134.20
Low?$133.94
Prev. Close?$134.08
Volume?1.9M
Avg. Volume?4.4M
VWAP?$134.01
Rel. Volume?0.42x
Bid / Ask
Bid?$133.10 × 100
Ask?$135.10 × 400
Spread?$2.00
Midpoint?$134.10
Valuation & Ratios
Market Cap?10.1B
Shares Out?61.9M
Float?48.8M
Float %?78.9%
P/E Ratio?N/A
P/B Ratio?8.07
EPS?-$3.63
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Employees
261
Market Cap
10.1B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2023-07-14
Address
221 CRESCENT ST.
WALTHAM, MA 02453
Phone: 650-394-5230
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+1/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
83
Piotroski F-Score?0/9Weak
Altman Z-Score?160.10Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.57%High
Short Interest?5.2M
Days to Cover?1.0
Free Float48.8M
Avg Daily Volume10.1M
Settlement Date2026-06-30
Financial Health
Current Ratio?32.59Strong
Quick Ratio?32.59Strong
Cash Ratio?13.71Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
Peers
100
S&P
23
8.07HIGH
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-32.1CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
7
-21.9%WEAK
ROA?
S&P
3
-21.2%WEAK
Cash Flow & Enterprise
FCF?$-235373000
Enterprise Value?$9.7B
Fundamentals ratios updated end of day